Subscribe
27 November 2017Big Pharma

MSD launches UK hub as government announces industrial strategy

MSD, known as Merck and Co in the US and Canada, announced plans to launch a life sciences discovery research facility just hours ahead of the UK government’s release of its industrial strategy.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UKIPO issues formal response to Industrial Strategy IP views
22 May 2018   The UK Intellectual Property Office has published several proposals, including some addressing barriers to growth for IP-rich companies, in response to received views of IP with regard to the government’s Industrial Strategy.
Europe
Regeneron forms consortium to fund exome sequencing
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
UKIPO issues formal response to Industrial Strategy IP views
22 May 2018   The UK Intellectual Property Office has published several proposals, including some addressing barriers to growth for IP-rich companies, in response to received views of IP with regard to the government’s Industrial Strategy.
Europe
Regeneron forms consortium to fund exome sequencing
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.

More on this story

Big Pharma
UKIPO issues formal response to Industrial Strategy IP views
22 May 2018   The UK Intellectual Property Office has published several proposals, including some addressing barriers to growth for IP-rich companies, in response to received views of IP with regard to the government’s Industrial Strategy.
Europe
Regeneron forms consortium to fund exome sequencing
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB